Shield Therapeutics (LSE:STX) Days Sales Outstanding

: 254.15 (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

Shield Therapeutics's average Accounts Receivable for the six months ended in Jun. 2023 was £6.04 Mil. Shield Therapeutics's Revenue for the six months ended in Jun. 2023 was £4.33 Mil. Hence, Shield Therapeutics's Days Sales Outstanding for the six months ended in Jun. 2023 was 254.15.

The historical rank and industry rank for Shield Therapeutics's Days Sales Outstanding or its related term are showing as below:

LSE:STX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.72 Med: 28.82 Max: 324.65
Current: 324.65

During the past 9 years, Shield Therapeutics's highest Days Sales Outstanding was 324.65. The lowest was 4.72. And the median was 28.82.

LSE:STX's Days Sales Outstanding is ranked worse than
97.6% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 72.07 vs LSE:STX: 324.65

Shield Therapeutics's Days Sales Outstanding increased from Jun. 2022 (183.41) to Jun. 2023 (254.15).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Shield Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Shield Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

4.72

129.96

7.70

124.35

148.10

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Days Sales Outstanding														420.21	247.20	183.41	356.87	254.15

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics Days Sales Outstanding Distribution

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Days Sales Outstanding falls into.

Shield Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Shield Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0.816	+	2.809)	/	2 )	/	4.467	*	365
=	1.8125					/	4.467	*	365
=	148.10

Shield Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding (Q: Jun. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )	*	Days in Period
=	( (2.809	+	9.262)	/	2 )	/	4.334	*	365 / 2
=	6.0355					/	4.334	*	365 / 2
=	254.15

Shield Therapeutics (LSE:STX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Shield Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.